Allergic asthma is a Th2-driven inflammatory process characterized by the infiltration of eosinophils into the airways. IL-5 is a key trigger for eosinophil expansion and release from the bone marrow and plays a crucial role in the entire life span of eosinophils from differentiation to maturation and survival. IL-5 can be considered among the most obvious targets to selectively inhibit eosinophilic airway inflammation. Areas covered: The preclinical and clinical development of reslizumab, a humanized mAb against IL-5 that has been developed to block IL-5 bioactivity and reduce biologically available IL-5, are described with a particular focus on its pharmacodynamics (PK)/pharmacokinetic (PD) profile. Expert opinion: Although pivotal trials have documented that reslizumab can be recommended as add-on therapy for the treatment of patients with severe eosinophilic asthma, there is still important information that is lacking and some PK and PD properties of reslizumab are still not fully understood.

Matera, M.g., Rogliani, P., Calzetta, L., & Cazzola, M. (2018). Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 14(2), 239-245 [10.1080/17425255.2018.1421170].

Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma

Rogliani P.;Calzetta L.;Cazzola M.
2018

Abstract

Allergic asthma is a Th2-driven inflammatory process characterized by the infiltration of eosinophils into the airways. IL-5 is a key trigger for eosinophil expansion and release from the bone marrow and plays a crucial role in the entire life span of eosinophils from differentiation to maturation and survival. IL-5 can be considered among the most obvious targets to selectively inhibit eosinophilic airway inflammation. Areas covered: The preclinical and clinical development of reslizumab, a humanized mAb against IL-5 that has been developed to block IL-5 bioactivity and reduce biologically available IL-5, are described with a particular focus on its pharmacodynamics (PK)/pharmacokinetic (PD) profile. Expert opinion: Although pivotal trials have documented that reslizumab can be recommended as add-on therapy for the treatment of patients with severe eosinophilic asthma, there is still important information that is lacking and some PK and PD properties of reslizumab are still not fully understood.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/10 - Malattie dell'Apparato Respiratorio
English
Con Impact Factor ISI
Asthma; eosinophils; humanized monoclonal antibody; interleukin-5; reslizumab
Matera, M.g., Rogliani, P., Calzetta, L., & Cazzola, M. (2018). Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 14(2), 239-245 [10.1080/17425255.2018.1421170].
Matera, Mg; Rogliani, P; Calzetta, L; Cazzola, M
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/193280
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 8
social impact